SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2021 / Cilt: 55 - Sayı: 2

Retrospective Assessment of Ventilator-Associated Pneumonias due to Acinetobacter baumannii in an Oncology Hospital

Mustafa ERTEK
Sevil Yesim CANTURAN
Zuhal AVŞAR
Nadim YILMAZER
İlhan UYANER
Rukiye SARIKAYA
Pages
193–196
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Keywords: Acinetobacter baumannii; intensive care unit; oncology hospital; ventilator-associated pneumonia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Ventilator-associated pneumonia (VAP) is associated with significant morbidity and mortality in critically ill patients and leads to increases in health-care costs.
📊
Key Findings & Data:However, it is preventable, and hospitals can decrease VAP rates.
💡
Conclusion & Impact:Keywords: Acinetobacter baumannii; intensive care unit; oncology hospital; ventilator-associated pneumonia.
🔬Design:Lab & Field Experiment
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Ventilator-associated pneumonia (VAP) is associated with significant morbidity and mortality in critically ill patients and leads to increases in health-care costs. However, it is preventable, and hospitals can decrease VAP rates. This study aims to retrospectively assess VAP rates in the intensive care unit of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital of the University of Health Sciences, with reference to Acinetobacter baumannii, one of the causative organisms. Methods: This study enrolled a total of 2277 patients hospitalized between the years of 2011 and 2015. The required data were collected by reviewing medical files of the patients through computerized hospital databases. VAP rate and ventilator utilization (VU) ratio were calculated using the United States Center for Disease Control National Healthcare Safety Network methodology. Results: Of the study patients, 302 (13.26%) were seen to have developed VAP. Among these patients, 191 (63.25%) were microbiologically diagnosed VAP caused by A. baumannii. Pooled means of VU ratio and VAP rate were 0.70 and 22.91, respectively. Conclusion: The results of this study will motivate the infection control committee of the study hospital to assess current infection control program and strategies so that high VAP rate in the study intensive care unit can be reduced to the minimum possible level. Keywords: Acinetobacter baumannii; intensive care unit; oncology hospital; ventilator-associated pneumonia.

🔖

Cite This Article

ERTEK, M., CANTURAN, S. Y., AVŞAR, Z., YILMAZER, N., UYANER, İ., SARIKAYA, R. (2022). Retrospective Assessment of Ventilator-Associated Pneumonias due to Acinetobacter baumannii in an Oncology Hospital. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 55 - Sayı: 2, 193–196. https://ajindex.com/articles/594632

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Karasu D, Yılmaz C, Durmuş G, Özer D, Çağlayan Ü, Karaduman İ, et al. Evaluation of healthcare-associated infections in critically Ill patients receiving long-term treatment in the intensive care unit. Klimik Dergisi 2016;29:71–6
  2. Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K, Turki O, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis 2013;17:e1225–8
  3. Özgür ES, Horasan ES, Karaca K, Ersöz G, Naycı Atış S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control 2014;42:206–8
  4. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006;19:637– 57
  5. Wagh H, Acharya D. Ventilator associated pneumonia - an overview. BJMP 2009;2:16–9
  6. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J Biol Sci 2018;25:586– 96
  7. Karaoglan H, Yalcin AN, Cengiz M, Ramazanoglu A, Ogunc D, Hakan R, et al. Cost analysis of ventilator-associated pneumonia in Turkish medical-surgical intensive care units. Infez Med 2010;18:248–55
  8. Alp E, Kalin G, Coskun R, Sungur M, Guven M, Doganay M. Economic burden of ventilator-associated pneumonia in a developing country. J Hosp Infect 2012;81:128–30
  9. Park DR. The microbiology of ventilator-associated pneumonia. Respir Care 2005;50:742–63; discussion 763–5
  10. Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care 2014;18:208
  11. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254–63
  12. Tomak Y, Ertürk A, Şen A, Erdivanlı B, Kurt A. Ventilator-associated pneumonia rate and causative microorganisms in an anesthesia intensive care unit. Sisli Etfal Hastan Tip Bul 2012;46:115–9
  13. Arda B. Nosocomial infections: diagnosis of ventilator-sssociated pneumonia. ANKEM Derg 2014;28:208–11
  14. Bailey KL, Kalil AC. Ventilator-associated pneumonia (VAP) with multidrug-resistant (MDR) pathogens: optimal treatment? Curr Infect Dis Rep 2015;17:494
  15. Almomani BA, McCullough A, Gharaibeh R, Samrah S, Mahasneh F. Incidence and predictors of 14-day mortality in multidrugresistant Acinetobacter baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015;9:1323–30
  16. But A, Yetkin MA, K